TrialInternational journal of cancer2022

Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.

Erik van Dijk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.